Head & neck · 2013
Treatment and prognosis in sinonasal mucosal melanoma: A retrospective analysis of 65 patients from a single cancer center.
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sun Chuan-Zheng, Li Qiu-Li, Hu Ze-Dong, Jiang Yu-E, Song Ming, Yang An-Kui
Аннотация
BACKGROUND: The purpose of this study was to evaluate the outcome in sinonasal mucosal melanoma (SMM).
METHODS: A retrospective analysis of clinicopathological data from January 1976 to December 2005 was performed. Survival curve, univariate, and multivariate analyses were undertaken.
RESULTS: Sixty-eight patients with SMM were enrolled; 3 patients refused treatment. The 3-year and 5-year overall survival (OS) rates in the remaining 65 cases of SMM were 36.5% and 29.7%, respectively. Patients who underwent surgery had better 3-year and 5-year OS rates than those treated without surgery (40.7% and 34.1% vs 21.4% and 14.3%, respectively), and the same was true for patients treated with and without biotherapy (58.2% and 50.9% vs 30.0% and 23.4%, respectively). Distant metastasis at presentation was associated with a worse prognosis. Those patients managed with multimodality treatment had better OS rates.
CONCLUSION: The prognosis in SMM is poor, particularly for those with distant metastasis or without surgery. Multimodality treatment may improve survival.
METHODS: A retrospective analysis of clinicopathological data from January 1976 to December 2005 was performed. Survival curve, univariate, and multivariate analyses were undertaken.
RESULTS: Sixty-eight patients with SMM were enrolled; 3 patients refused treatment. The 3-year and 5-year overall survival (OS) rates in the remaining 65 cases of SMM were 36.5% and 29.7%, respectively. Patients who underwent surgery had better 3-year and 5-year OS rates than those treated without surgery (40.7% and 34.1% vs 21.4% and 14.3%, respectively), and the same was true for patients treated with and without biotherapy (58.2% and 50.9% vs 30.0% and 23.4%, respectively). Distant metastasis at presentation was associated with a worse prognosis. Those patients managed with multimodality treatment had better OS rates.
CONCLUSION: The prognosis in SMM is poor, particularly for those with distant metastasis or without surgery. Multimodality treatment may improve survival.
Предметные рубрики MeSH
AdolescentAdultAgedAnalysis of VarianceAntineoplastic AgentsBCG VaccineCancer Care FacilitiesChi-Square DistributionChildChild, PreschoolCohort StudiesCombined Modality TherapyConfidence IntervalsDisease-Free SurvivalDose Fractionation, RadiationFemaleHumansInterferon alpha-2Interferon-alphaInterleukin-6MaleMelanomaMiddle AgedMultivariate AnalysisNasal MucosaNasal Surgical ProceduresNeoplasm InvasivenessNeoplasm StagingParanasal Sinus NeoplasmsProportional Hazards ModelsRadiotherapy, AdjuvantRecombinant ProteinsRetrospective StudiesRisk AssessmentSurvival RateTreatment OutcomeYoung Adult